We further analyzed the tumor, spleen, and peripheral blood and found increased numbers of CD3+ T (both CD4+ and CD8+ T cells) in the combination-treatment groups, whereas the numbers of CD4+ FoxP3+ T cells were decreased. This evidence concerns the gene FOXP3 and neoplasm.